Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728064 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01728064 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT01728064, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
Interventions
- DRUG Placebo
- DRUG EPI-743 400 mg
- DRUG EPI-743 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-12-31 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728064
The ClinicalTrials.gov registry entry for NCT01728064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01728064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728064 about?
NCT01728064 is a clinical study titled "Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia". The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
What is the current status of trial NCT01728064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2012-12-31. Estimated completion is 2016-02-29.
What interventions are being tested in trial NCT01728064?
The interventions under investigation include: Placebo (DRUG), EPI-743 400 mg (DRUG), EPI-743 200 mg (DRUG).
Who is sponsoring clinical trial NCT01728064?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.